53 search results for: disease control
Translating the Science of CSU: From Pathogenesis to Patient Outcomes
Watch as Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, importance of disease control, and emerging therapies.
Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU
Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.
ADVENT at EAACI 2025
Join Profs. Brian Lipworth, Zuzana Diamant, and Philippe Gevaert at an sponsored symposium about the latest strategies for the management of co-existing type 2 asthma and severe and/or uncontrolled CRSwNP.
2025 ADVENT Forum | Joint Plenary Session: A View into the Life of Our Patients Video
This cross-TA plenary session addressed challenges in type 2 inflammation-driven diseases. Esteemed faculty, including Profs Klaus Rabe, Sharon Dell, Anju Peters, Milli Gupta, Eric Simpson, Stella Lee, and moderator Oscar Palomares, discussed strategies to enhance quality of life, reduce disease burden, and prioritize patient-centered care.
Adult Asthma Interactive Patient Cases
Explore 3 hypothetical patient cases using guideline-based checklists for assessment and diagnosis of type 2 inflammation in adult asthma
Connecting Type 2 Inflammation to CRSwNP
Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.
European Society for Pediatric Dermatology (ESPD) 2024 | Košice, Slovakia
Inflammatory processes drive AD both within and beyond the skin, leading to significant, cumulative life impacts. Early intervention has the potential to mitigate these impacts by altering the disease course.
CRSwNP: A Chronic Type 2 Inflammatory Disease
Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.
ADVENT On Air | Expert Discussions in Dermatology
Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.
EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Join Professor Joaquim Mullol for a discussion of the emerging concept of clinical remission in CRSwNP.
Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.
